iOncologi, Inc. (www.ioncologi.com), a clinical-stage biopharmaceutical company pioneering novel immunotherapies for cancer treatment, today announced the appointment of Dr. Mona Flores and Mr. Paolo Fundarò to its Board of Directors. Their combined expertise in AI-driven healthcare innovation, biopharmaceutical leadership, and strategic biotech investment will strengthen iOncologi’s mission to rapidly advance its breakthrough immunotherapy platforms.
“We are thrilled to welcome Dr. Mona Flores and Mr. Paolo Fundarò to our Board of Directors,” said Dr. Edgardo Rodriguez-Lebron, Ph.D., CEO of iOncologi. “Dr. Flores’ leadership in innovative AI-guided healthcare solutions and Mr. Fundarò’s extensive experience in life sciences investment and company building bring invaluable insights as we advance breakthrough immunotherapy technologies in the fight against solid tumor cancers.“
“The future of immuno-oncology lies at the intersection of AI, precision medicine, and breakthrough therapeutics. I am excited to join iOncologi’s Board and contribute to its mission of harnessing advanced AI-driven insights to accelerate the development of transformative cancer therapies that improve patient outcomes,” said Dr. Mona Flores.
“I am thrilled to join the board of this groundbreaking biotech company dedicated to fighting difficult-to-treat cancers. I look forward to working alongside a team committed to advancing innovative solutions that have the potential to make a real difference in patients’ lives,” said Mr. Paolo Fundarò.
“We are extremely excited to welcome Dr. Mona Flores and Mr. Paolo Fundarò to the iOncologi Board,” said Dr. Duane A. Mitchell, Co-founder of iOncologi and Chairman of the Board. “Dr. Flores brings a wealth of leadership and operational experience, world-class expertise in medical AI, and a global perspective on how digital technologies and data science are transforming healthcare delivery and drug development. Importantly, she operates through the lens of a compassionate physician dedicated to improving the lives of patients and their families. iOncologi is fortunate to have her as part of our leadership team, and I look forward to working with Mona as an engaged member of our Board.”
Dr. Mitchell further added, “Paolo Fundarò brings industry-leading experience as a life sciences entrepreneur, biopharma founder, and strategic investor. His extensive expertise and deep global ties within the life sciences sector, particularly in Europe, will be invaluable in steering iOncologi’s development of next-generation immunotherapies.”
The appointment of Dr. Flores and Mr. Fundarò aligns with iOncologi’s commitment to assembling a world-class leadership team to accelerate the development of AI-guided, next-generation transformative immunotherapies for solid tumors.
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
